[go: up one dir, main page]

ES2084940T3 - Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. - Google Patents

Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.

Info

Publication number
ES2084940T3
ES2084940T3 ES92305287T ES92305287T ES2084940T3 ES 2084940 T3 ES2084940 T3 ES 2084940T3 ES 92305287 T ES92305287 T ES 92305287T ES 92305287 T ES92305287 T ES 92305287T ES 2084940 T3 ES2084940 T3 ES 2084940T3
Authority
ES
Spain
Prior art keywords
lymphoma
rapamicine
treatment
adult leukemia
atl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92305287T
Other languages
English (en)
Inventor
Glenn Alvin Miller
Mark Barry Rabin
William Joseph Jnr Harrington
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2084940T3 publication Critical patent/ES2084940T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTE INVENTO PROPORCIONA UN METODO PARA TRATAR CELULAS T ADULTAS DE LEUCEMIA/LINFOMA (ATL) EN UN MAMIFERO QUE LO NECESITE QUE COMPRENDE LA ADMINISTACION DE UNA CANTIDAD ANTIPROLIFERATIVA DE RAPAMICIN Y ES PARTICULARMENTE UTIL EN ATAJAR O HACER REMITIR ATL.
ES92305287T 1991-06-18 1992-06-09 Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas. Expired - Lifetime ES2084940T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US71777391A 1991-06-18 1991-06-18

Publications (1)

Publication Number Publication Date
ES2084940T3 true ES2084940T3 (es) 1996-05-16

Family

ID=24883429

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92305287T Expired - Lifetime ES2084940T3 (es) 1991-06-18 1992-06-09 Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.

Country Status (20)

Country Link
EP (1) EP0525960B1 (es)
JP (1) JP2562548B2 (es)
KR (1) KR930000115A (es)
AT (1) ATE135583T1 (es)
AU (1) AU651698B2 (es)
CA (1) CA2071456A1 (es)
CZ (1) CZ281663B6 (es)
DE (1) DE69209183T2 (es)
DK (1) DK0525960T3 (es)
ES (1) ES2084940T3 (es)
GR (1) GR3019749T3 (es)
HK (1) HK108897A (es)
HU (1) HU214326B (es)
IE (1) IE71646B1 (es)
IL (1) IL102185A (es)
MX (1) MX9202939A (es)
NZ (1) NZ243175A (es)
SG (1) SG43072A1 (es)
SK (1) SK279804B6 (es)
ZA (1) ZA924369B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
DE69430060T2 (de) 1993-04-23 2002-11-07 Abbott Laboratories, Abbott Park Antikörper von rapamycinen mit offenem ring
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5527907A (en) * 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
CA2175215C (en) * 1993-11-19 2008-06-03 Yat Sun Or Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5561138A (en) 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
FR2736550B1 (fr) 1995-07-14 1998-07-24 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
JP2001503061A (ja) * 1996-10-31 2001-03-06 アメリカン・ホーム・プロダクツ・コーポレイション ラパマイシンおよびカルシトリオールを含んでなる相乗組成物
CA2275889C (en) 1996-12-30 2008-03-18 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
CA2230748C (en) * 1997-03-14 2010-08-03 American Home Products Corporation Rapamycin formulations for oral administration
PT994697E (pt) * 1997-06-13 2005-02-28 Wyeth Corp Formulacoes de rapamicina para administracao oral
US5985325A (en) * 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
JP2002502820A (ja) * 1998-02-04 2002-01-29 アプライド・ジェネティクス・インコーポレーテッド・ダーマティクス 遺伝子毒性エージェントへの反応によるサイトカインの放出を調節する組成物及び方法
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
US6331547B1 (en) 1999-08-18 2001-12-18 American Home Products Corporation Water soluble SDZ RAD esters
WO2001051049A1 (en) * 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
US6670355B2 (en) 2000-06-16 2003-12-30 Wyeth Method of treating cardiovascular disease
EP1319008B1 (en) 2000-09-19 2008-10-15 Wyeth Water soluble rapamycin esters
US6399625B1 (en) 2000-09-27 2002-06-04 Wyeth 1-oxorapamycins
US6399626B1 (en) 2000-10-02 2002-06-04 Wyeth Hydroxyesters of 7-desmethylrapamycin
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
BR0210101A (pt) * 2001-06-01 2004-06-08 Wyeth Corp Combinações antineoplásticas
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
BR0211986A (pt) 2001-08-22 2004-09-28 Wyeth Corp 29-enóis de rapamicina
JP2005503395A (ja) 2001-08-22 2005-02-03 ワイス ラパマイシンジアルデヒド
US7026330B2 (en) * 2002-05-30 2006-04-11 The Children's Hospital Of Philadelphia Methods for treatment of acute lymphocytic leukemia
AR040693A1 (es) 2002-07-30 2005-04-13 Wyeth Corp Formulaciones parenterales
AR042938A1 (es) 2003-02-06 2005-07-06 Wyeth Corp Uso del cci-779 en el tratamiento de la fibrosis hepatica
DE602005010228D1 (de) 2004-04-14 2008-11-20 Wyeth Corp Verfahren zur herstellung von rapamycin-42-estern und fk-506-32-estern mit dicarbonsäure, vorstufen für rapamycinkonjugate und antikörper
ME02688B (me) 2004-05-13 2017-10-20 Icos Corp Hinazolinoni kao inhibitori humane fosfatidilinozitol 3 - kinaze delta
WO2005117889A1 (en) * 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
CA2629714A1 (en) 2005-11-14 2007-05-24 Ariad Gene Therapeutics, Inc. Administration of an mtor inhibitor to treat patients with cancer
EP2431036B1 (en) 2006-09-13 2017-04-12 Elixir Medical Corporation Macrocyclic lactone compounds and methods for their use
EP3427739A1 (en) 2008-11-13 2019-01-16 Gilead Calistoga LLC Therapies for hematologic malignancies
US9492449B2 (en) 2008-11-13 2016-11-15 Gilead Calistoga Llc Therapies for hematologic malignancies
CN102439012A (zh) 2009-03-24 2012-05-02 吉里德卡利斯托加公司 2-嘌呤基-3-甲苯基-喹唑啉酮衍生物的阻转异构体和使用方法
US8492110B2 (en) 2009-04-10 2013-07-23 Haiyan Qi Anti aging agents and methods to identify them
AU2010239312A1 (en) 2009-04-20 2011-11-10 Gilead Calistoga Llc Methods of treatment for solid tumors
KR20120049281A (ko) 2009-07-21 2012-05-16 길리아드 칼리스토가 엘엘씨 Ｐｉ３ｋ 억제제를 이용한 간 장애의 치료
MX2014007077A (es) 2011-12-16 2015-03-06 Pfizer Combinacion de inotuzumab ozogamicina y torisel para el tratamiento de cancer.
BR112014021935A2 (pt) 2012-03-05 2019-09-24 Gilead Calistoga Llc formas polimórficas de (s)-2(l-(9h-purin-6-ilamino)propil)-5-fluoro-3-fenilquinazolina-4(3h)ona
EP3594215A1 (en) 2013-12-20 2020-01-15 Gilead Calistoga LLC Intermediate products in process methods for the preparation of phosphatidylinositol 3-kinase inhibitors
AU2014364414A1 (en) 2013-12-20 2016-06-30 Gilead Calistoga Llc Polymorphic forms of a hydrochloride salt of (S) -2-(1-(9H-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3H) -one
EP3154960A1 (en) 2014-06-13 2017-04-19 Gilead Sciences, Inc. Phosphatidylinositol 3-kinase inhibitors
JP2020507632A (ja) 2017-02-10 2020-03-12 マウント タム セラピューティクス, インコーポレイテッドMount Tam Therapeutics, Inc. ラパマイシン類似体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
GB8610114D0 (en) * 1986-04-25 1986-05-29 Esselte Letraset Ltd Sign-making materials

Also Published As

Publication number Publication date
DE69209183D1 (de) 1996-04-25
HUT61480A (en) 1993-01-28
NZ243175A (en) 1997-06-24
SG43072A1 (en) 1997-10-17
JPH05170771A (ja) 1993-07-09
EP0525960A1 (en) 1993-02-03
SK279804B6 (sk) 1999-04-13
KR930000115A (ko) 1993-01-15
ZA924369B (en) 1993-12-15
CZ281663B6 (cs) 1996-12-11
JP2562548B2 (ja) 1996-12-11
GR3019749T3 (en) 1996-07-31
IE921957A1 (en) 1992-12-30
MX9202939A (es) 1994-05-31
DK0525960T3 (da) 1996-04-15
HU214326B (hu) 1998-03-02
CA2071456A1 (en) 1992-12-19
HK108897A (en) 1997-08-22
HU9202023D0 (en) 1992-09-28
IE71646B1 (en) 1997-02-26
IL102185A (en) 1997-09-30
DE69209183T2 (de) 1996-08-08
AU651698B2 (en) 1994-07-28
ATE135583T1 (de) 1996-04-15
CZ182492A3 (en) 1993-12-15
AU1825592A (en) 1992-12-24
EP0525960B1 (en) 1996-03-20
SK182492A3 (en) 1994-10-05

Similar Documents

Publication Publication Date Title
ES2084940T3 (es) Uso de la rapamicina para el tratamiento de la leucemia/linfoma de las celulas t adultas.
DE69118407D1 (de) Vorrichtung zum Steuern der Seitenverschiebung eines Endlos-Bandes und damit ausgestattetes Fixiergerät
LV11116A (lv) Virsmas notirisana ar apstarojuma palidzibu
DK0414289T3 (da) Spirocykliske, antipsykotiske midler
ES2056180T3 (es) Nuevos derivados de 2'-halometiliden, 2'-eteniliden y 2'-etinil citidina.
DE69030848D1 (de) Wafertisch und damit versehene Belichtungsvorrichtung
DE68908231D1 (de) Roentgenuntersuchungsapparat mit einstellbarer schlitzfoermiger blende.
DE68904029D1 (de) Sicherheitsgurtvorrichtung.
ES2089723T3 (es) 29-demetoxirapamicina para inducir la inmunodepresion.
ITRM930318A0 (it) Dispositivo di ritegno del pezzo di punta per pattino di supporto di un nastro abrasivo.
DE69205694D1 (de) Schleifband und Verfahren zu dessen Herstellung.
FI870506A0 (fi) Saollningsanlaeggning med sammanbygd foerdelnings- och avskiljningsanordning.
DK0458589T3 (da) Behandling af okulær hypertension med en okulær synergistisk kombination
DK0458590T3 (da) Behandling af okulær hypertension med en synergistisk konbination
DE69014221D1 (de) Bandführungsvorrichtung.
PT656209E (pt) Derivados de melatonina para uso no tratamento de perturbacoes de dessincronizacao
FI903742A0 (fi) Foerfarande foer diskontinuerlig framstaellning av l-carnitin pao mikrobiologisk vaeg.
ATE242663T1 (de) Vorrichtung zur vermessung und sortierung von werkstücken
DE59200188D1 (de) Gurtaufroller mit Komforteinrichtung.
DE58900132D1 (de) Verfahren und vorrichtung zum montieren von riemen an riementrieben.
ATE83907T1 (de) Vorrichtung zum offenhalten eines ureterotomieschnitts.
NO884787D0 (no) Opptaks- og transportinnretning for arbeidsstykker.
ITTO920702A0 (it) Apparecchio per vulcanizzare cinghie di gomma senza fine
ATE160756T1 (de) Förderbandsystem und heizapparat in dem das system anwendung findet
DE69013938D1 (de) Sicherheitsgurtvorrichtung.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 525960

Country of ref document: ES